A number of other research analysts have also issued reports on the company. Citigroup reiterated a buy rating on shares of AstraZeneca in a research report on Thursday, September 7th. Natixis upgraded AstraZeneca from a neutral rating to a buy rating and boosted their price target for the stock from GBX 5,000 ($67.29) to GBX 5,738 ($77.23) in a research report on Wednesday, September 6th. Deutsche Bank reiterated a buy rating and set a GBX 5,300 ($71.33) price target on shares of AstraZeneca in a research report on Tuesday, September 5th. Liberum Capital reiterated a buy rating and set a GBX 4,800 ($64.60) price target on shares of AstraZeneca in a research report on Tuesday, September 5th. Finally, Societe Generale reiterated a buy rating on shares of AstraZeneca in a research report on Monday, September 11th. Four research analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. AstraZeneca currently has an average rating of Hold and a consensus target price of GBX 5,169 ($69.57).
AstraZeneca (LON:AZN) opened at GBX 4,886.50 ($65.77) on Friday. AstraZeneca has a 12-month low of GBX 4,136.50 ($55.67) and a 12-month high of GBX 5,520 ($74.29).
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.